Florin Court Capital LLP Makes New Investment in iShares Biotechnology ETF $IBB

Florin Court Capital LLP acquired a new stake in iShares Biotechnology ETF (NASDAQ:IBB) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 77,000 shares of the financial services provider’s stock, valued at approximately $11,116,000. iShares Biotechnology ETF accounts for about 8.7% of Florin Court Capital LLP’s investment portfolio, making the stock its 2nd biggest holding. Florin Court Capital LLP owned 0.18% of iShares Biotechnology ETF at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. SG Americas Securities LLC grew its stake in shares of iShares Biotechnology ETF by 96.3% in the third quarter. SG Americas Securities LLC now owns 28,569 shares of the financial services provider’s stock worth $4,125,000 after acquiring an additional 14,016 shares in the last quarter. Viewpoint Capital Management LLC boosted its holdings in iShares Biotechnology ETF by 1,532.1% in the third quarter. Viewpoint Capital Management LLC now owns 12,730 shares of the financial services provider’s stock valued at $1,838,000 after purchasing an additional 11,950 shares during the period. Bronte Capital Management Pty Ltd. grew its stake in iShares Biotechnology ETF by 12.6% during the 2nd quarter. Bronte Capital Management Pty Ltd. now owns 295,346 shares of the financial services provider’s stock worth $37,000 after purchasing an additional 32,947 shares in the last quarter. Employees Retirement System of Texas purchased a new stake in iShares Biotechnology ETF during the 2nd quarter worth about $25,049,000. Finally, D.A. Davidson & CO. raised its position in iShares Biotechnology ETF by 181.0% in the 3rd quarter. D.A. Davidson & CO. now owns 13,701 shares of the financial services provider’s stock valued at $1,978,000 after purchasing an additional 8,825 shares in the last quarter. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of iShares Biotechnology ETF stock opened at $176.90 on Wednesday. The business has a 50-day simple moving average of $170.97 and a 200-day simple moving average of $153.86. iShares Biotechnology ETF has a one year low of $107.43 and a one year high of $179.64.

iShares Biotechnology ETF Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 19th. Shareholders of record on Tuesday, December 16th were given a $0.1831 dividend. The ex-dividend date of this dividend was Tuesday, December 16th. This represents a $0.73 dividend on an annualized basis and a dividend yield of 0.4%. This is a boost from iShares Biotechnology ETF’s previous quarterly dividend of $0.08.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.